Market Overview
Global Ultrasonic Nebuliser market size was valued at USD 1.691 billion in 2024. The market is projected to reach USD 2.297 billion by 2031, exhibiting a CAGR of 4.6% during the forecast period.
An ultrasonic nebuliser is a device that uses high-frequency vibrations to deliver medication in mist form. This technology breaks down liquid medication into fine aerosol particles, which patients inhale via a mask or mouthpiece for effective respiratory treatment. Ultrasonic nebulisers are widely applied in managing conditions such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other respiratory ailments. Key types include portable models for home use and floor-standing units for clinical settings.
USD 1.691 billion in 2024
2032 USD 2.297 billion by 2031
of 4.6%
Portable Segment Dominates the Market Due to Rising Demand for Home-Based
Respiratory Care
The market is segmented based on type into:
Portable Floor Standing
Portable ultrasonic nebulisers hold the largest share owing to their convenience, compact design, and suitability for personal use at home or during travel, aligning with the growing trend of self-managed chronic disease treatment. Floor-standing models, while less dominant, remain essential in clinical and hospital environments for their higher capacity and stability in delivering consistent aerosol therapy to multiple patients.
By Application
Asthma Segment Leads Due to
Cystic Fibrosis
Asthma
Others
Our Key Players
Omron Healthcare (Japan)
Philips Respironics (U.S.)
PARI Medical (Germany)
Medline Industries (U.S.)
Rossmax (Taiwan)
Medtronic (Ireland)
Becton Dickinson (U.S.)
https://www.24lifesciences.com/dow
https://www.24lifesciences.com
